AbbVie Inc. (ABBV)
NYSE · Healthcare · Drug Manufacturers - General
$265.76+1.12%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $470B
- P/E (trailing)
- 75.1
- Forward P/E
- 16.4
- Dividend yield
- 2.6%
- 52-week range
- $190.75 – $269.39
- 52-week change
- +14.14%
- EPS (trailing)
- $3.54
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 30, 2026
Fiscal year to Dec 2025
- Revenue
- $61.2B (+8.57%)
- Net income
- $4.2B
- Operating margin
- 24.6%
- Diluted EPS
- $2.36
- Free cash flow
- $17.8B
From the company’s annual report on SEC EDGAR.
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
Headquarters: North Chicago, United States · 57,000 employees · abbvie.com